MUFG Securities EMEA plc Makes New $8.85 Million Investment in Kenvue Inc. $KVUE

MUFG Securities EMEA plc acquired a new position in shares of Kenvue Inc. (NYSE:KVUE) in the 2nd quarter, HoldingsChannel reports. The fund acquired 422,999 shares of the company’s stock, valued at approximately $8,853,000.

Other institutional investors also recently modified their holdings of the company. Evergreen Wealth Solutions LLC boosted its stake in Kenvue by 2.6% during the first quarter. Evergreen Wealth Solutions LLC now owns 16,769 shares of the company’s stock worth $402,000 after acquiring an additional 432 shares in the last quarter. Wealth Alliance LLC increased its stake in Kenvue by 1.6% in the first quarter. Wealth Alliance LLC now owns 31,778 shares of the company’s stock valued at $762,000 after purchasing an additional 486 shares in the last quarter. Everett Harris & Co. CA raised its holdings in shares of Kenvue by 1.4% during the first quarter. Everett Harris & Co. CA now owns 36,971 shares of the company’s stock valued at $887,000 after purchasing an additional 500 shares during the period. Proffitt & Goodson Inc. boosted its position in shares of Kenvue by 8.2% during the 2nd quarter. Proffitt & Goodson Inc. now owns 6,831 shares of the company’s stock worth $143,000 after purchasing an additional 517 shares in the last quarter. Finally, UMB Bank n.a. boosted its position in shares of Kenvue by 22.3% during the 2nd quarter. UMB Bank n.a. now owns 2,853 shares of the company’s stock worth $60,000 after purchasing an additional 521 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Up 1.1%

Shares of NYSE:KVUE opened at $14.40 on Friday. The business’s 50 day moving average is $17.21 and its 200 day moving average is $20.51. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $25.17. The stock has a market cap of $27.63 billion, a price-to-earnings ratio of 19.45, a PEG ratio of 2.07 and a beta of 0.72. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The business had revenue of $3.84 billion during the quarter, compared to analyst estimates of $3.94 billion. During the same period in the prior year, the firm posted $0.32 EPS. Kenvue’s quarterly revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, sell-side analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th will be given a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.8%. The ex-dividend date of this dividend is Wednesday, November 12th. Kenvue’s dividend payout ratio (DPR) is presently 112.16%.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. UBS Group decreased their target price on Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a research report on Wednesday, October 8th. JPMorgan Chase & Co. reduced their price objective on Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Johnson Rice reaffirmed a “neutral” rating on shares of Kenvue in a research report on Tuesday. Bank of America lowered their target price on Kenvue from $25.00 to $21.00 and set a “buy” rating on the stock in a research report on Wednesday, October 8th. Finally, Rothschild & Co Redburn raised shares of Kenvue from a “neutral” rating to a “buy” rating and reduced their price target for the company from $22.50 to $22.00 in a research report on Friday, September 26th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Kenvue has an average rating of “Hold” and a consensus price target of $20.17.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.